Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant

Leukemia and Lymphoma

Volumn 55, Issue 8, 2014, Pages 1922-1924

  Von Tresckow, Bastian ^a,b   Müller, Horst ^a,b   Eichenauer, Dennis A ^a,b   Glossmann, Jan P ^a   Josting, Andreas ^c   Böll, Boris ^a,b   Klimm, Beate ^a,b   Sasse, Stephanie ^a,b   Fuchs, Michael ^a,b   Borchmann, Peter ^a,b   Engert, Andreas ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b German Hodgkin Study Group (GHSG)   (Germany)

^c OnkoBer   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; FEMALE; HODGKIN DISEASE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; AUTOTRANSPLANTATION; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; PATHOLOGY; TUMOR RECURRENCE;

DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PATIENT OUTCOME ASSESSMENT; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84902456895     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.854888     Document Type: Letter

References (17)

1. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-652.
2. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. J Clin Oncol 2012; 30: 907-913.
3. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791-1799.
4. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
5. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071.
6. Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010; 28: 5074-5080.
7. Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009; 146: 158-163.
8. Kaloyannidis P, Voutiadou G, Baltadakis I, et al. Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 451-457.
9. Sureda A, Constans M, Iriondo A, et al. Prognostic factors aff ecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. A nn Oncol 2005; 16: 625-633.
10. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012; 30: 2197-2203.
11. Younes A, Gopal A K, Smith S E, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-2189.
12. Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013; 24: 2430-2434.
13. Arai S, Fanale M, Devos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 2013; 54: 2531-2533.
14. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20: 221-230.
15. von Tresckow B, Engert A. The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant. Expert Rev Hematol 2012; 5: 483-486.
16. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119: 1665-1670.
17. Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin Lymphoma responding to prior salvage therapy. Haematologica 2012; 97: 1073-1079.